Kalorama Information market research studies have the data you need on the drug discovery market opportunity, providing analysis, projections, and information on market direction. Drug discovery operations can prove time-consuming and difficult, and may come at a high economic cost, which has driven outsourcing in this field. Kalorama explores an important segment, the contract research organization segment, looking in detail at an approach that is helping to shape the drug discovery market today.
- Display 45 Products per page
Published: May 1, 2003 | Price: $2,062.00 – $4,152.00
The number and scope of drug discovery outsourcing agreements has grown rapidly over the past five years, and the pace will accelerate over the next five years. Outsourcing is now an essential part of drug discovery. Major pharmas and biotechs are aggressively pursuing a range of outsourcing agreements. On the supplier side, smaller vendors rely on outsourcing revenues to pay their bills and boost their credibility. Outsourcing in drug discovery is a popular topic for trade articles and seminars. These...Published: August 1, 2003 | Price: $2,625.00 – $5,250.00
This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include: · Men’s Cancer · Sexual Function · Sexually Transmitted Diseases · Urinary Conditions · Andropause The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product...Published: August 1, 2003 | Price: $1,496.00 – $2,992.00
The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama Information’s March 2003 publication Women’s Health: Worldwide Prescription Drug Markets, 3rd Edition, we embarked on a supplemental study that goes beyond the prescription market to...Published: November 1, 2003 | Price: $1,875.00 – $3,750.00
The process of creating a new drug is lengthy and complex. From discovery to development to market, there are numerous pitfalls. In this report, Kalorama focuses on one of the trickiest yet also most promising areas: the interface between discovery and development known as lead optimization. The pressure is on: get better lead compounds faster and at less cost. The amount of money wasted on leads that fail is excessive. And the attrition rate to get a lead is huge....Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: May 1, 2005 | Price: $3,000.00 – $6,000.00
Within the world of life science research, informatics plays a key role. A few years ago, this market space was occupied primarily by a few niche players, but over the past five years, established companies have expanded their offerings and hundreds of new software companies have surfaced. In the rapidly changing field of informatics, it is difficult to decode the buzz-words, interpret the extravagant claims, separate true needs from blue-sky wishes. The concerns and strategies of only a year ago...Published: January 1, 2006 | Price: $2,995.00 – $5,990.00
In the Spring of 2003, Kalorama published its first report on Outsourcing in Drug Discovery. Since then, so much has changed, the use of the term "2nd Edition" hardly seems appropriate. This new study involved completely re-examining the market from the ground up. This new report is designed to make readers aware of the enormous changes that are taking place in the drug discovery outsourcing market, and the forces that are shaping the sector. It presents viewpoints from both customers...Published: May 1, 2006 | Price: $3,500.00 – $7,000.00
CRO is a need-to know practice in pharmaceutical marketing today; but information is not always easy to find. This second edition of Kalorama’s best-selling look at the clinical contract research industry provides the key information competitors need to navigate the complexities and costs of clinical research in the drug development process. In addition to a comprehensive discussion of the market and regulatory environment, the report details: the size and nature of the drug research pipeline, the size and growth of...Published: September 1, 2006 | Price: $3,900.00 – $7,800.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...Published: June 1, 2007 | Price: $1,990.00 – $6,990.00
Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that...Published: June 1, 2007 | Price: $995.00 – $1,990.00
The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion people worldwide suffer from tuberculosis, and it is now presenting a major crisis in public health circles. As illustrated by Kenneth G. Krul, Phd., in Kalorama Information's Global Tuberculosis Strategies, there are abundant opportunities for diagnostic and pharmaceutical companies in combating the global tuberculosis threat. As the author details, there are primarily three focal...Published: November 1, 2007 | Price: $1,500.00 – $7,000.00
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: May 1, 2008 | Price: $3,500.00 – $7,000.00
2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations....Published: August 1, 2008 | Price: $1,500.00 – $4,995.00
Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study. This report includes incidence of Alzheimer’s disease worldwide with information...Published: October 1, 2008 | Price: $3,500.00 – $7,000.00
Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. Kalorama Information's Outsourcing in Drug Development is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues. Part of the CMO Market Series,...Published: January 1, 2009 | Price: $995.00 – $7,000.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...Published: February 1, 2009 | Price: $3,995.00 – $7,590.00
This Kalorama Information report - Clinical Nutrition - focuses on three primary segments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort) Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients) Parenteral Nutrition For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall...Published: October 1, 2009 | Price: $3,500.00 – $7,000.00
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of...Published: June 1, 2010 | Price: $3,995.00 – $7,990.00
Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 22 suppliers, representative of those active in this market. Segments covered in this report include: Chemistry Services Building Blocks Compound Synthesis Libraries Process Research Other Services Biology Services Protein...Published: May 11, 2012 | Price: $3,995.00 – $7,990.00
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery...Published: December 4, 2012 | Price: $500.00 – $1,000.00
This Kalorama Information report – The Next Wave in Cancer Treatment--Kinase Inhibitors - is focused on a growing area of cancer treatment, kinase inhibitors. Several cancers are being treated with these newer therapies, which provide a focus of cancer profiled in this report, including: Breast Colorectal Head/Neck Kidney Leukemia Liver Lung Melanoma Ovarian Pancreatic Prostate Stomach The report covers both currently marketed and late stage development kinase inhibitors for cancer treatment. Revenues for this market segment were generated using dollar...Published: May 20, 2013 | Price: $1,500.00 – $2,250.00
The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain...Published: April 30, 2014 | Price: $995.00 – $1,990.00
For six editions, this authoritative resource has defined the market opportunity for companies assisting in the beginning phase of the drug development process. This Kalorama Information Report, Outsourcing in Drug Discovery, t provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. As part of its coverage, the report provides markets and forecasts for the following segments. Chemistry Services Market: Building Blocks, Compound Synthesis, Libraries,...Published: April 26, 2016 | Price: $3,360.00 – $6,720.00
Outsourcing in Drug Discovery, 7th Edition This Kalorama Information study, Outsourcing in Drug Discovery, provides details estimates and forecasts of the contract research organization market and an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market. As part of its coverage, the report provides markets and forecasts for chemistry, biology and lead optimization. The report also provides an overview of the CRO drug discovery process, and...Published: March 20, 2018 | Price: $4,500.00 – $9,000.00
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 8th Edition In eight editions, Kalorama Information's report, Outsourcing in Drug Discovery, has kept the industry informed, providing answers to these questions and more. The 8th edition contains 2017 market size estimates and 2022 forecasts for 21 different parts of the process that might be outsourced, including: Chemistry Services Market, 2017-2022 Building Blocks Outsourcing Market, 2017-2022 Compound Synthesis Market, 2017-2022 Library Construction Market, 2017-2022 Process Research Market, 2017-2022 Biology Services...Published: March 27, 2018 | Price: $0.00
This brief White Paper lists over one hundred companies that are involved in drug discovery in one form or another. A company website and address is provided for each company. The White Paper does not detail companies or discuss the CRO marketplace - for this purpose, please consult our recent report, Outsourcing in Drug Discovery, 8th Edition.Published: July 19, 2018 | Price: $4,500.00 – $9,000.00
In Vitro Toxicology In Vitro Toxicology analyses global in vitro toxicity testing markets and various market segments with the objective to identify the important market trends that will bring further growth in this market. The study aims to derive crucial insights that will benefit all the major stakeholders of the industry in developing strategic business plans based on these emerging trends. The report provides market size and growth trends for various toxicity endpoint segments for 2018-2023, including ADME-Tox; cytotoxicity; genotoxicity;...